XRTX

Companies
NASDAQ
Xortx Therapeutics Inc.
Health Care
Price Chart
Overview

About XRTX

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Market Cap
$6.9M
Volume
38.8K
Avg. Volume
49.5K
P/E Ratio
-0.60479045
Dividend Yield
0.00%
Employees
2.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.18
Low Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for XRTX.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, XRTX shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$6.9M
Volume38.8K
P/E Ratio-0.60
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 16, 2023
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how XRTX fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025